Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 1998

View Archived Issues

Company Profile: OSI Pharmaceuticals

Novo Nordisk and Aradigm to develop pulmonary insulin delivery system

Company Profile: Adolor

Pfizer discloses indazole inhibitors of PDE and TNF production

Encouraging results reported for Cel-Sci's Multikine

Vapreotide, RC-3940-II and cetrorelix: novel peptide analogues for treating renal cell carcinoma

Excellent phase III results reported for bropirimine in CIS

Eisai trims its product pipeline

JTT-501, a novel treatment for NIDDM

tgAAV-CFTR research results published in The Lancet

New antiallergic and antiinflammatory compounds developed by Astra researchers

Novel rapamycin derivatives patented by AHP

Warner-Lambert team describes preferential inhibitors of MMP-2 and MMP-3

Pfizer team reveals heterobicyclic CRF antagonists

Neuroprotective agents based on enzyme inhibition prepared at P&U

BMS/IRORI strategic alliance to develop ultra-high-throughput combinatorial chemistry system

Duke University pioneers novel therapy for GBM

Astra stops development of local anesthetic

More on Ilex Oncology's chemopreventive agent

First European clearance for Eisai's Pariet

Combination immunotherapy of renal cell carcinoma: efficacy established in phase II trial

Maxamine plus IFN-alpha appears effective and safe in nonresponding HCV patients

Alexion C5 inhibitor provides protection from damage in animal heart attack model

SSRIs versus tricyclics as regards risk of hip fracture in the elderly

Mechanism of neuroprotective effect of selegiline; efficacy in HIV-associated dementia

ET antagonist protects against ciclosporin-induced nephrotoxicity in rats

NexMed begins clinical trials of female sexual dysfunction product

CNI-H0294, an anti-HIV agent with a unique mechanism of action

French regulatory approval obtained for AmBisome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...